Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer

Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient

(2020) Ana Belén Lozano et al.   ANTIVIRAL RESEARCH

Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis

(2020) Sarah E Moore et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus–positive patient with esophageal cancer

(2020) Patricia Pecora Fulco   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

(2019) Olga Kaplun et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration

(2017) Kristina M. Brooks et al.   PHARMACOTHERAPY

Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection

(2016) L. Buscemi   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY